Table 1.
Patient, tumor, and treatment characteristics
| Characteristic | No. (%) (n=109) |
|---|---|
| Age (yr) | |
| < 45 | 29 (27) |
| ≥ 45 | 80 (73) |
| Histology | |
| IDC | 100 (92) |
| Non-IDC | 9 (8) |
| T stage | |
| T1 | 61 (56) |
| T1a | 2 (2) |
| T1b | 15 (14) |
| T1c | 44 (40) |
| T2 | 48 (44) |
| LVI | |
| Negative | 102 (94) |
| Positive | 7 (6) |
| No. of positive lymph nodes | |
| 1 | 69 (63) |
| 2 | 29 (27) |
| 3 | 11 (10) |
| Percentage of positive lymph nodes | |
| < 25 | 103 (94) |
| ≥ 25 | 6 (6) |
| ECE | |
| Negative | 100 (92) |
| Positive | 9 (8) |
| Histological grade | |
| 1 | 21 (20) |
| 2 | 60 (57) |
| 3 | 25 (24) |
| Estrogen receptor status | |
| Negative | 25 (23) |
| Positive | 84 (77) |
| Progesterone receptor status | |
| Negative | 48 (44) |
| Positive | 61 (56) |
| HER2 overexpression | |
| Negative | 73 (69) |
| Positive | 33 (31) |
| Systemic chemotherapy and/or hormone therapy | 105 (96) |
| Chemotherapy | 94 (86) |
| AC±T | 75 (69) |
| CMF | 14 (13) |
| Unspecified | 5 (5) |
| Hormone therapy | 58 (53) |
| Post-mastectomy radiotherapy | |
| No | 72 (66) |
| Yes | 37 (34) |
IDC, invasive ductal carcinoma; LVI, lymphovascular invasion; ECE, extracapsular extension; AC, adriamycin cyclophosphamide; T, paclitaxel docetaxel; CMF, cyclophosphamide methotrexate 5-fluorouracil.